By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


Company News
Agios Pharmaceuticals (AGIO) To Webcast Conference Call Of Second Quarter 2014 Financial Results On August 7, 2014 7/28/2014 7:40:02 AM
New Agios Pharmaceuticals (AGIO) Clinical Data From Ongoing Phase 1 Trial Of AG-221 Continue To Show Complete And Durable Remissions In Patients With Difficult To Treat Hematologic Malignancies 6/16/2014 10:19:30 AM
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-221 For Treatment Of Acute Myelogenous Leukemia 6/16/2014 7:45:23 AM
Celgene Corporation (CELG) Grabs Rights To Agios Pharmaceuticals (AGIO)' Lead Cancer Drug 6/13/2014 6:58:05 AM
Agios Pharmaceuticals (AGIO) Initiates Multiple Ascending Dose Trial In Healthy Volunteers Of AG-348 For The Potential Treatment Of PK Deficiency, A Rare, Hemolytic Anemia 6/9/2014 8:32:00 AM
Agios Pharmaceuticals (AGIO) Reports First Quarter 2014 Financial Results 5/8/2014 9:26:01 AM
Agios Pharmaceuticals (AGIO) To Webcast Conference Call Of First Quarter 2014 Financial Results On May 8, 2014 5/1/2014 2:43:40 PM
Agios Pharmaceuticals (AGIO) Announces Proposed Offering Of Common Stock 4/22/2014 7:56:35 AM
Agios Pharmaceuticals (AGIO) Initiates Phase 1 Study Of AG-348, A First-in-class PKR Activator, For Pyruvate Kinase Deficiency 4/17/2014 9:30:24 AM
Whoa. Agios Pharmaceuticals (AGIO)'s Experimental Cancer Drug Makes Cancer Undetectable In Three Patients 4/7/2014 7:31:23 AM